Merkel cell polyomavirus (MCPyV) and ambient ultraviolet radiation (UVR) exposure account for most Merkel cell carcinoma (MCC) cases in the United States. Researchers evaluated 38,020 MCC cases (38% ...

A multidisciplinary team from University of Washington and Fred Hutchinson Cancer Research Center has received a five-year, $12 million grant to study Merkel cell carcinoma, a deadly form of skin ...

Merkel cell polyomavirus is one of seven viruses known to cause cancer in humans. Infection with this virus is asymptomatic, but, rarely, it can lead to the development of Merkel cell carcinoma (MCC), ...

A common pinworm medication may stop and reverse cancer growth in Merkel cell carcinoma, an aggressive form of skin cancer, according to research led by University of Arizona Cancer Center researchers ...

In a prospective study of patients with stages I-III Merkel cell carcinoma (MCC), seropositivity for rising polyomavirus oncoprotein antibody titers conferred a 58% risk for recurrence at 12 months, ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in the Journal of Clinical Oncology highlighting the ...

Merkel cell carcinoma is a rare but fast-growing neuroendocrine cancer that is three to five times more likely than melanoma to be deadly. Response rates to current therapies—surgery, radiation and ...

"Parrotheads" and casual fans of Caribbean living mourned the death of "Margaritaville" singer Jimmy Buffett over the weekend, who died at the age of 76 after a years-long battle with a rare and ...

A new cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) shows that a drug that utilizes the body's immune system to target and eliminate cancer cells appeared to reduce the ...

A drug that harnesses the immune system to attack cancer cells has proved successful in preventing a rare and aggressive form of skin cancer from spreading to other organs when given immediately after ...

Tumor-wide RNA splicing aberrations and their potential as therapeutic neoantigen targets. Phase 1/2, open-label, first-in-human study of the anti-GPC3 T-cell engager SAR444200 in patients with ...

Please provide your email address to receive an email when new articles are posted on . Pyrvinium pamoate showed promise in reducing the size of Merkel cell carcinoma tumors. Researchers “excited” ...